Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
David R GandaraJanakiraman SubramanianEdgardo S SantosYehuda BrodyItamar SelaYehonatan ElonMichal HarelAnat Reiner-BenaimCoren LahavKimberly McGregorPublished in: Clinical lung cancer (2024)
Adding PROphet to PD-L1 expression impacted therapeutic decision making in first-line NSCLC. PROphet identifies those predicted to have an overall survival benefit from ICI monotherapy versus combination versus chemotherapy, improving the probability of efficacy and reducing toxicity for some patients.
Keyphrases
- end stage renal disease
- decision making
- ejection fraction
- newly diagnosed
- small cell lung cancer
- primary care
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- radiation therapy
- oxidative stress
- cell cycle
- patient reported outcomes
- clinical trial
- advanced non small cell lung cancer
- open label
- locally advanced
- free survival
- cell proliferation
- dna methylation
- patient reported
- study protocol
- tyrosine kinase